161 related articles for article (PubMed ID: 37586872)
1. Detection bias in open-label trials of anticancer drugs: a meta-epidemiological study.
Funada S; Luo Y; Kataoka Y; Yoshioka T; Fujita Y; Yoshida S; Katsura M; Tada M; Nishioka N; Nakamura Y; Ueno K; Uozumi R; Furukawa TA
BMJ Evid Based Med; 2023 Nov; 28(6):372-382. PubMed ID: 37586872
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. Inadequate reporting of adjudicators in open-label trials of anticancer drugs between 2017 and 2021: a methodological review.
Funada S; Luo Y; Kataoka Y; Yoshioka T; Fujita Y; Yoshida S; Katsura M; Tada M; Nishioka N; Nakamura Y; Furukawa TA
J Clin Epidemiol; 2022 Oct; 150():80-89. PubMed ID: 35792261
[TBL] [Abstract][Full Text] [Related]
4. Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour.
Zhang J; Zhang Y; Tang S; Jiang L; He Q; Hamblin LT; He J; Xu Z; Wu J; Chen Y; Liang H; Chen D; Huang Y; Wang X; Deng K; Jiang S; Zhou J; Xu J; Chen X; Liang W; He J
BMJ Open; 2018 Sep; 8(9):e017240. PubMed ID: 30206071
[TBL] [Abstract][Full Text] [Related]
5. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Phase 2 Oncology Trials.
Dello Russo C; Cappoli N; Pilunni D; Navarra P
J Clin Pharmacol; 2021 Jun; 61(6):810-819. PubMed ID: 33244770
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
7. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib for the treatment of multiple myeloma.
Scott K; Hayden PJ; Will A; Wheatley K; Coyne I
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD010816. PubMed ID: 27096326
[TBL] [Abstract][Full Text] [Related]
9. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia.
Bauer K; Rancea M; Roloff V; Elter T; Hallek M; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11(11):CD008079. PubMed ID: 23152253
[TBL] [Abstract][Full Text] [Related]
10. Alemtuzumab for patients with chronic lymphocytic leukaemia.
Skoetz N; Bauer K; Elter T; Monsef I; Roloff V; Hallek M; Engert A
Cochrane Database Syst Rev; 2012 Feb; 2012(2):CD008078. PubMed ID: 22336834
[TBL] [Abstract][Full Text] [Related]
11. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
12. Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations.
Solomon BJ; Loong HH; Summers Y; Thomas ZM; French P; Lin BK; Sashegyi A; Wolf J; Yang JC; Drilon A
ESMO Open; 2022 Apr; 7(2):100398. PubMed ID: 35183043
[TBL] [Abstract][Full Text] [Related]
13. Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials: A Systematic Review and Meta-analysis.
Kok PS; Cho D; Yoon WH; Ritchie G; Marschner I; Lord S; Friedlander M; Simes J; Lee CK
JAMA Netw Open; 2020 Sep; 3(9):e2011809. PubMed ID: 32897371
[TBL] [Abstract][Full Text] [Related]
14. Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis.
Ritchie G; Gasper H; Man J; Lord S; Marschner I; Friedlander M; Lee CK
JAMA Oncol; 2018 Apr; 4(4):522-528. PubMed ID: 29470579
[TBL] [Abstract][Full Text] [Related]
15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.
Lian Q; Fredrickson J; Boudier K; Rothkegel C; Hilton M; Hillebrecht A; McDonald A; Xu N
Oncologist; 2023 Mar; ():. PubMed ID: 36905580
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes.
Hutzschenreuter F; Monsef I; Kreuzer KA; Engert A; Skoetz N
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD009310. PubMed ID: 26880256
[TBL] [Abstract][Full Text] [Related]
18. Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis.
Blumenthal GM; Zhang L; Zhang H; Kazandjian D; Khozin S; Tang S; Goldberg K; Sridhara R; Keegan P; Pazdur R
JAMA Oncol; 2017 Aug; 3(8):e171029. PubMed ID: 28617920
[TBL] [Abstract][Full Text] [Related]
19. Local Investigators Significantly Overestimate Overall Response Rates Compared to Blinded Independent Central Reviews in Uncontrolled Oncology Trials: A Comprehensive Review of the Literature.
Dello Russo C; Navarra P
Front Pharmacol; 2022; 13():858354. PubMed ID: 35652050
[TBL] [Abstract][Full Text] [Related]
20. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
